男性乳腺癌：附17例报告

目的:探讨男性乳腺癌的诊断、治疗及预后。方法:回顾性分析17例男性乳腺癌患者的临床资料。结果:17例患者平均年龄为59.6岁。其中Ⅰ期3例，Ⅱ期5例，Ⅲ期7例，Ⅳ期2例。以典型浸润性导管癌为主，乳腺癌的雌、孕激素受体阳性率分别为82.4 %和72.5 %。均行根治性手术治疗，术后辅以放疗、内分泌治疗和（或）化疗。其中1例失访，2例术后8个月~3年死于其它疾病，余14例术后已生存1～12年。结论:男性乳腺癌发病率低，发病年龄偏大,易误诊;内分泌治疗首选他莫昔芬;影响其预后的因素很多，其中最重要的是诊断时肿瘤的分期和淋巴结受累情况。

Male breast cancer:a report of 17 cases

Abstract:Objective:To explore the diagnosis, treatment and prognosis of male breast cancer.Methods :The clinical data of 17 male patients with breast cancer were analyzed retrospectively.Results:The average age of these 17 patients was 59.6 years. In these 17 male cases, the breast cancer in 3 cases was stageⅠ, in 5 cases stageⅡ,in 7 cases stage Ⅲ, and in 2 cases stage Ⅳ. The major pathological type was typical invasive ductal carcinoma. The breast cancer positive rates of estrogen receptor was 82.4 % and progestogen receptor (PR) was 72.5 %. All of these cases were treated by radical operation and postoperative adjuvant radiotherapy, endocrine therapy and (or) chemotherapy. One patient was lost to follow-up, 2 died of non-tumor disease 8 months and 3 years after operation, respectively, and the other 14 have survived for 1-12 years after operation.Conclusions:Male breast cancer is an uncommon disease, age of onset is more advanced, and the misdiagnostic rate is high. Tamoxifen is the first choice of hormone therapy. Many factors influence the prognosis of male breast cancer, the most important of which are the TNM stage of tumor, and condition of lymph node involvement.